Home > News > Board Recommends Continuation of Medidur(TM) Trial
March 20th, 2006
Board Recommends Continuation of Medidur(TM) Trial
Abstract:
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and pSivida Limited, a global
bio-nanotech company, announced today that following a planned interim review, an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 3 clinical trial of Medidur(TM).
Source:
newswire.ca
Related News Press |
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||